Can Stage 1 triple-negative breast cancer be cured?

It may be treatable, but it’s usually not curable. TNBC has a high recurrence rate, which is greatest within the first 3 years. However, there’s a sharp reduction in recurrence after 5 years.

What medication is used for triple-negative breast cancer?

Common chemotherapies for triple negative breast cancer may include an anthracycline such as Adriamycin, alkylating agents such as Cytoxan, and a taxane, such as Taxol or Taxotere. Fluorouracil (5FU) may be given as well. Often a combination of drugs, or a “chemo cocktail,” is given to disable and kill cancer cells.

What are the chances of surviving triple-negative breast cancer?

The five-year survival rate for someone with localized triple-negative breast cancer, cancer that has not spread beyond the breast, is 91 percent (91 percent as likely as someone without cancer to survive during the five-year period).

Is triple-negative breast cancer the worst kind?

Triple-negative breast cancer (TNBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.

What is the life expectancy of someone with triple negative breast cancer?

The median survival was approximately 4 months in patients with triple-negative breast cancer, 9 months in those with HER2-positive breast cancer, and 15 months in those with luminal (hormone receptor–positive) breast cancer.

Why is triple negative breast cancer so hard to treat?

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted drugs work. If the cancer has not spread to distant sites, surgery is an option.

What is triple negative breast cancer and how is it treated?

Big Changes Coming in Treatment of Triple-Negative Breast Cancer Refining Chemotherapy for TNBC. In a phase 3 trial, 1 labeled Study 301, Halaven (eribulin mesylate) was compared with the chemotherapy capecitabine in previously treated patients with locally advanced or Novel Strategies in TNBC. Androgen Receptor Signaling.

What is the survival rate for triple negative breast cancer?

Only 40 percent of those who get the disease survive for three years. The survival rate for triple-negative breast cancer patients as a whole is 70 percent. Triple-negative cancers test negative for estrogen receptors, progesterone receptors, and HER2.